111 Capital Takes $2.79 Million Position in Zoetis Inc. (NYSE:ZTS)

111 Capital bought a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, Holdings Channel reports. The fund bought 17,101 shares of the company’s stock, valued at approximately $2,786,000.

A number of other large investors have also added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its position in shares of Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC bought a new position in Zoetis during the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the 4th quarter valued at $44,000. Finally, Asset Planning Inc acquired a new position in Zoetis during the 4th quarter worth $58,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, May 12th. UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Stifel Nicolaus lowered their price target on Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a report on Monday, April 14th. Finally, Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $212.75.

Zoetis Stock Performance

Shares of ZTS opened at $166.23 on Wednesday. The firm has a fifty day moving average of $156.53 and a 200-day moving average of $164.69. The company has a market cap of $74.01 billion, a price-to-earnings ratio of 30.39, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis’s revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.38 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is presently 35.91%.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.18% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.